M&A | Partnerships

Vilex will market and distribute Royal Biologics' portfolio of Autologous and Live Cellular therapies for lower extremity orthopedic procedures.

The merger will create a company positioned with products and specialized salesforces serving hospital, ambulatory surgical center and office care settings.

Exactech's Optecure demineralized bone matrix will complement RTI Surgical's portfolio of bone graft substitutes.

The group purchasing agreement for Synthetic Implantable Products allows Premier members to access pricing and terms for CERAMENT bone void filler.

Kuros has signed a sales agency agreement with various entities, covering the Netherlands, Switzerland, Austria and Finland.

The transaction includes GUIDOR bone graft substitutes known as easy-graft and calc-i-oss, and builds on the company's strategy to expand its technologies.

Over 25,000 of Theracell's licensed demineralized bone fiber products have been delivered by the company's licensee partners.

The expanded agreement with Australian Biotechnologies includes exclusive rights to market demineralized fiber grafts for Australia and New Zealand.

The company and its partners formed TrueBone3D to develop biologically active, patient-tailored bioresorbable implants enriched with ALLOB.

OssDsign expects to see revenue from Osteo3 ZP bone graft substitute putty during 2H21 following approval processes in U.S. hospitals.